30-day average of 21 articles · scale −100 to +100
Across 21 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Novo Nordisk A/S news is Slightly Bullish (+24)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+5).
📈 Novo Nordisk surpassed JPMorgan forecasts with 8M+ cumulative Wegovy prescriptions.
📉 Operating profit dropped 9% YoY due to planned high-volume, low-price shift.
Somewhat Bullish +45
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo ...
AI-generated analysis
Key insights
📈 Novo Nordisk exceeded JPMorgan analyst predictions with over eight million cumulative prescriptions for its Wegovy pill since launch.
💊 The company's oral GLP-1 pill has achieved even greater market success than the initial injection-based Wegovy shot.
📉 Operating profit fell 9% year over year as the company executes a planned strategic shift to a high-volume, low-price business model.
💰 Novo Nordisk offers a 4.4% dividend yield, which is well above the pharmaceutical industry average of 1.3%.
📉 The stock has declined 70% from its 2024 peak, trading at price-to-sales and price-to-earnings ratios below five-year averages.
⚠️ The company faces competition from Eli Lilly's existing GLP-1 pill and other rivals waiting to enter the market with their own drugs.
📈 Bullish signals
📈Novo Nordisk successfully launched its Wegovy pill, accumulating over eight million cumulative prescriptions since the product's introduction.
💊The company's oral GLP-1 pill has proven more successful in adoption than the initial injection-based Wegovy shot.
💰Novo Nordisk offers a 4.4% dividend yield, which is significantly higher than the pharmaceutical sector average of 1.3%.
📉The stock trades at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios.
📉Strong adoption rates for the Wegovy pill indicate that the company's strategic transition to a high-volume model is progressing as planned.
📉 Risk factors
📉Operating profit fell 9% year over year in the quarter due to the deliberate shift toward a low-price, high-volume business model.
📉Current revenues and earnings are being depressed by the company's strategic pricing strategy during this transition period.
⚠️Novo Nordisk faces direct competition from Eli Lilly, which already has its own GLP-1 pill on the market.
Article
Novo Nordisk (NYSE: NVO) has successfully met JPMorgan analyst expectations for strong sales of its Wegovy oral pill, having accumulated over eight million cumulative prescriptions since the product's launch. The company was the first to market with a GLP-1 weight-loss shot and subsequently the first to introduce the pill format, which has proven even more successful than the injection in terms of adoption.
Despite this strong product performance, Novo Nordisk reported a 9% year-over-year decline in operating profit for the quarter. Management attributes this decline to a strategic shift toward a high-volume, low-price business model designed to maximize market penetration. While revenues and earnings are currently depressed by this pricing strategy during what the company defines as a transition year, the strong adoption rates suggest the long-term plan is progressing as intended.
The stock has fallen 70% from its 2024 peak, trading at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios. It offers a 4.4% dividend yield, significantly higher than the pharmaceutical sector average of 1.3%, supported by a strong 33% payout ratio. While conservative investors may prefer to wait for profits to fully reflect the new model, the current risk/reward balance appears tilted toward reward for income and value-oriented investors.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Novo Nordisk shares declined by 2.13 percent to DKK 253.3 on September 23, 2026, following renewed speculation regarding a potential direct listing on the New York Stock Exchange. While CEO Mike Doustdar stated the company is open to considering such a move to replace its current American depositary receipt structure, he clarified that no formal process has been initiated and the company is not actively exploring the change at this time.
The Danish pharmaceutical giant continues to execute its capital return program aggressively, having repurchased approximately 34.2 million B shares for DKK 9.63 billion by September 18. These buybacks accounted for 64.2 percent of the company's DKK 15 billion, 12-month authorization, with the average purchase price of DKK 281.79 standing significantly above the current market price of DKK 253.3.
Analyst sentiment remains cautious regarding immediate upside, with Berenberg maintaining a Neutral rating and a DKK 305 price target as of September 22. Novo Nordisk's market capitalization stood at DKK 1.13 trillion on September 23, trading within a 52-week range between DKK 224.3 and its high of DKK 410.0.
Despite the stock being 38.2 percent below its 52-week high, the company remains primarily listed in Copenhagen with US investors accessing shares via ADRs. The potential shift to a direct listing represents a strategic market-access decision rather than an immediate alteration to the underlying business operations or financial performance.
📉 Novo Nordisk stock fell 2.13 percent to DKK 253.3 on September 23, 2026, amid debate over a potential direct New York Stock Exchange listing.
🗣️ CEO Mike Doustdar confirmed the company is open to considering a direct NYSE listing but emphasized it is not actively exploring the change or has started a formal process.
💰 The company repurchased 34.17 million B shares for DKK 9.63 billion by September 18, utilizing 64.2 percent of its DKK 15 billion buyback program.
📊 Novo Nordisk traded at DKK 253.3, which is 38.2 percent below its 52-week high of DKK 410.0 and 28.49 below the average buyback price.
🏦 Berenberg maintained a Neutral rating with a DKK 305 price target, implying approximately 20.4 percent upside from the September 23 market price.
📈 Novo Nordisk holds a market capitalization of DKK 1.13 trillion and operates in the Healthcare / Drug Manufacturers - General sector.
Bullish Signals
Buybacks: 34.17M shares for DKK 9.63B (64.2% of program).
Novo Nordisk has executed significant share buybacks, purchasing 34.17 million shares for DKK 9.63 billion, representing 64.2 percent of its authorized DKK 15 billion program.
The average price paid during buybacks was DKK 281.79, indicating management's confidence that the stock is undervalued relative to the repurchase cost.
Risk Factors
Novo Nordisk shares declined 2.13 percent to DKK 253.3 on September 23, trading 38.2 percent below its 52-week high of DKK 410.0.
Analyst Berenberg maintains a Neutral rating with a price target of DKK 305, suggesting limited immediate upside from the current market price.
Novo Nordisk is considering replacing its American Depositary Receipts (ADRs) with a direct listing on the New York Stock Exchange to enhance its profile among US investors, though the company states it is not actively pursuing this change. CEO Mike Doustdar highlighted that US operations currently generate approximately 56% of the group's sales, making American market visibility critical as the company faces intensifying competition from Eli Lilly in the obesity drug sector.
The strategic discussion comes amidst investor concerns regarding Novo's growth trajectory following a recent capital markets day where shares fell about 8%. While Novo outlined plans to launch at least five potential blockbuster medicines by 2030 and generate over DKK150 billion in pipeline sales, analysts warn that the company remains heavily dependent on semaglutide, which could still represent nearly 60% of sales even after patent exclusivity begins to wane.
Wall Street analysts have downgraded Novo Nordisk due to fears that its medium-term growth ambitions are too conservative compared to the exceptional expansion seen previously. Morgan Stanley recently lowered its rating to Underweight, citing a valuation that does not fully reflect subdued growth expectations and the looming patent cliff. Consequently, while a direct listing might improve liquidity and visibility, it is viewed as secondary to the core investment questions of pipeline diversification and execution against competitors like Eli Lilly.
🏢 Novo Nordisk explores NYSE direct listing to boost US market profile.
📉 Shares fell 8% as capital markets day failed to reassure investors.
💊 CEO notes oral treatments could capture 50% of global obesity market by 2030.
📅 Company plans five blockbuster medicines by 2030 and DKK150B pipeline sales by 2035.
⚠️ Analysts warn semaglutide may represent 60% of 2031 sales, demanding diversification.
🏢 Novo Nordisk is exploring a switch from ADRs to a direct NYSE listing to boost its profile in the US market, where 56% of sales are generated.
📉 Shares fell approximately 8% after a capital markets day failed to reassure investors about the company's medium-term growth ambitions amidst fierce competition.
💊 CEO Mike Doustdar emphasized that while oral treatments could capture up to 50% of the global obesity market by 2030, the strategy must overcome challenges from Eli Lilly's injectable dominance.
📅 Novo plans to launch at least five potential blockbuster medicines by 2030 and generate over DKK150 billion in risk-adjusted pipeline sales by 2035.
⚠️ Analysts warn that semaglutide could still represent nearly 60% of sales in 2031, highlighting the critical need for successful diversification beyond the current blockbuster molecule.
📉 Morgan Stanley downgraded Novo Nordisk to Underweight, arguing the valuation does not fully reflect subdued growth expectations and the implications of the patent cliff.
🔮 Analyst forecasts predict only 2% to 3% revenue growth in 2027 and roughly 4% annual growth from 2027 through 2030, reflecting cautious market sentiment.
📊 AlphaValue analyst Abhishek Raval maintains a Buy rating but calls for aggressive diversification bets alongside strong commercial execution to reduce dependence on one molecule.
🏛️ A direct listing could improve visibility and liquidity but cannot by itself repair confidence in Novo's growth trajectory or replace future semaglutide revenue.
Bullish Signals
US ops drive 56% of group sales.
CEO sees oral treatments at 50% obesity market share by 2030.
Plans five blockbusters with DKK150B pipeline sales by 2035.
Risk Factors
Shares fell 8% amid growth ambition questions.
Morgan Stanley downgraded to Underweight on valuation.
Analysts forecast only 2-3% revenue growth in 2027.
Semaglutide patent cliff looms with 59% sales impact.
Bullish Signals
US operations generate about 56% of the group's sales, making American investors central to the company's future growth strategy.
CEO Mike Doustdar projects that oral treatments could account for as much as 50% of the global obesity-drug market by 2030, significantly above current Wall Street forecasts.
Novo outlined plans to launch at least five potential blockbuster medicines by 2030 and generate more than DKK150 billion in risk-adjusted pipeline sales by 2035.
Risk Factors
Shares fell about 8% as investors questioned a medium-term growth ambition closer to the broader pharmaceutical industry than the exceptional expansion Novo once delivered.
Morgan Stanley recently downgraded Novo Nordisk to Underweight, arguing that its valuation does not entirely reflect subdued medium-term growth or the implications of the semaglutide patent cliff.
Analysts forecast only 2% to 3% revenue and EBIT growth in 2027 and roughly 4% annual growth from 2027 through 2030, indicating cautious expectations for future performance.
The company faces a looming patent cliff where semaglutide could still represent 59% of sales in 2031 when loss-of-exclusivity effects begin to emerge.
Novo Nordisk (NVO) shares fell nearly 8% following a capital markets day that failed to alleviate investor concerns regarding the company's long-term pipeline. The sell-off occurred as investors viewed the company's targets as already priced in, leading CEO Mike Doustdar to acknowledge the need to rebuild trust after a period of perceived overpromising and underdelivering.
The central challenge facing Novo Nordisk is the impending patent expiry for its blockbuster drugs Ozempic and Wegovy, which account for roughly three-quarters of sales. With expiries looming in the early 2030s, the company faces a narrow window to develop replacement revenue streams. CEO Doustdar highlighted that while the company aims for five new blockbuster drugs by 2030, it is actively considering acquisitions in adjacent therapeutic areas like cardiovascular disease after its own experimental drug failed in trials.
Investor sentiment remains cautious regarding specific pipeline candidates, particularly CagriSema, which underperformed Eli Lilly's Zepbound in a recent head-to-head trial. Despite these challenges, Novo Nordisk continues to execute on its capital strategy, having repurchased approximately 34.17 million B shares for DKK 9.63 billion since February as part of a larger buyback program. Analysts currently maintain a Hold rating with a price target of $47.00 against a market cap of roughly $191.7 billion.
📉 Stock dropped 8% as long-term pipeline targets viewed as already priced in.
🗣️ CEO admits credibility issues from past overpromising on growth expectations.
⏳ Ozempic and Wegovy face patent expiries in US/Europe during early 2030s.
🔬 Cardiovascular drug ziltivekimab failed to reduce heart attack risk in trials.
💊 CagriSema delivered less weight loss than Eli Lilly's Zepbound in head-to-head trial.
📉 Novo Nordisk stock dropped nearly 8% after investors viewed the company's long-term pipeline targets as already priced in rather than a surprise.
🗣️ CEO Mike Doustdar admitted the company faces a credibility issue due to past overpromising and underdelivering on growth expectations.
⏳ Ozempic and Wegovy, comprising roughly 75% of sales, face patent expiries in the US and Europe during the early 2030s.
🔬 The company's experimental cardiovascular drug ziltivekimab failed to reduce heart attack risk in a clinical trial earlier this year.
💊 CagriSema delivered less weight loss than Eli Lilly's Zepbound in a head-to-head trial, tempering commercial expectations for the launch.
📈 Novo Nordisk repurchased 1.09 million B shares between September 14 and 18, bringing total buybacks to DKK 9.63 billion since February.
🎯 The company targets over five new blockbuster drugs by 2030 and aims for more than $23 billion in new sales by 2035.
🤝 CEO Doustdar indicated a shift toward acquiring assets in adjacent therapeutic areas like cardiovascular disease due to fewer attractive obesity targets.
📊 The most recent analyst rating is a Hold with a price target of $47.00, while the stock trades at a market cap of approximately $191.7 billion.
Bullish Signals
Repurchased 34.17M B shares for DKK 9.63B since Feb.
CEO expects CagriSema to be a strong launch next year.
Risk Factors
Stock dropped 8% due to Ozempic/Wegovy patent expiry fears.
CagriSema underperformed Lilly's Zepbound in trials.
Bullish Signals
Novo Nordisk continues to execute its share buyback program, having repurchased 34.17 million B shares for DKK 9.63 billion since February.
CEO Mike Doustdar expects the next-generation weight-loss candidate CagriSema to be one of the company's strongest launches next year.
Risk Factors
Novo Nordisk stock dropped nearly 8% as investors were not reassured about the company's ability to replace revenue from Ozempic and Wegovy before patent expiries in the early 2030s.
The company faces a credibility problem after CEO Mike Doustdar admitted that overpromising and underdelivering has eroded investor trust.
Novo's experimental drug ziltivekimab failed to reduce heart attack risk in a clinical trial, forcing the company to consider acquisitions to fill the cardiovascular gap.
CagriSema delivered less weight loss than Eli Lilly's Zepbound in a head-to-head trial, putting pressure on how Novo positions the drug commercially.
Novo-Nordisk ADR shares opened on September 21, 2026, following a modest 0.1% gain to close the previous session at USD 43.23 on September 18. The stock traded within an intraday range of USD 42.78 to USD 43.54 with approximately 10.36 million shares changing hands, reflecting active investor participation despite a trading price significantly below its 52-week high of roughly USD 64.16.
Company-specific developments are driving the current market focus as Novo-Nordisk announced the acquisition of three new obesity research and development programs from biotechnology firm Kallyope on September 18. This strategic move aims to broaden the company's cardiometabolic pipeline beyond its existing GLP-1 therapies, signaling a continued commitment to expanding its portfolio in the high-growth obesity treatment sector.
Looking ahead, Novo-Nordisk is hosting a capital markets day on September 21, 2026, starting at 09:00 BST. The event is expected to detail the company's semaglutide strategy and long-term growth assumptions, with market commentary suggesting that semaglutide could contribute approximately 75% of total sales for 2026, highlighting the critical importance of this flagship drug to the company's financial outlook.
📈 Novo-Nordisk ADR shares closed at USD 43.23 on September 18, 2026.
🔬 Company acquired three obesity R&D programs from Kallyope to expand pipeline.
💰 Semaglutide estimated to contribute about 75% of total sales for 2026.
🗓️ Capital markets day scheduled for September 21, 2026, to discuss strategy.
📉 Stock trades over USD 20 below its 52-week high of USD 64.16.
📈 Novo-Nordisk ADR shares closed at USD 43.23 on September 18, 2026, marking a 0.1% gain with trading volume of approximately 10.36 million shares.
🔬 The company announced the acquisition of three new obesity R&D programs from Kallyope to expand its cardiometabolic pipeline beyond current GLP-1 therapies.
🗓️ Novo-Nordisk is holding a capital markets day on September 21, 2026, to discuss semaglutide strategy and long-term growth assumptions.
💰 Analyst estimates suggest semaglutide may contribute about 75% of Novo-Nordisk's total sales for the year 2026.
📉 The current stock price of USD 43.23 trades more than USD 20 below its 52-week high of approximately USD 64.16.
Bullish Signals
Acquiring three obesity R&D programs from Kallyope.
Hosting capital markets day on Sept 21, 2026.
Risk Factors
Stock trades $20+ below 52-week high of $64.16.
Volume normal; no investor surge despite news.
Bullish Signals
Novo-Nordisk is acquiring three new obesity R&D programs from Kallyope to broaden its cardiometabolic pipeline beyond existing GLP-1 therapies.
The company is hosting a capital markets day on September 21, 2026, to present its semaglutide strategy and long-term growth assumptions to investors.
Risk Factors
Novo-Nordisk stock is trading at USD 43.23, which is more than USD 20 below its 52-week high of approximately USD 64.16.
Trading volume of 10.36 million shares was roughly in line with recent activity, indicating no significant surge in investor interest despite the news.
A new study published in September 2026 reveals that patients on the lowest starter doses of GLP-1 weight-loss drugs still achieve measurable weight loss, though significantly less than at full recommended doses. Specifically, low-dose tirzepatide from Eli Lilly produced a 5.5% average weight loss over one year compared to 2.2% for Novo Nordisk's low-dose semaglutide. While lower doses reduce side effects like nausea, they also result in substantially reduced efficacy compared to higher therapeutic regimens.
The research highlights a critical trade-off between tolerability and revenue potential for both companies. If patients remain on lower starter doses due to cost or side-effect concerns, prescription volume may grow without corresponding revenue growth per patient. This dynamic is particularly challenging for Novo Nordisk, whose low-dose semaglutide showed weaker performance relative to Lilly's tirzepatide in this specific dosage bracket.
Despite these findings, the expanding obesity market presents significant opportunities for both firms, with analysts projecting the sector to exceed $100 billion annually by 2030. Novo Nordisk continues to pursue growth through its oral obesity treatments like Wegovy pills and next-generation pipeline assets such as CagriSema. However, Lilly's superior low-dose efficacy and existing market leadership in injectables maintain a competitive advantage that pressures Novo's strategic position.
Investor sentiment reflects these dynamics, with hedge fund data showing a surge in holdings for Eli Lilly while Novo Nordisk sees more modest increases. The study underscores the importance of treatment intensity for revenue generation, suggesting that Novo must leverage its oral formulations and pipeline innovations to regain momentum against Lilly's dominant market share and stronger drug performance.
📉 Tirzepatide shows 5.5% weight loss vs 2.2% for semaglutide at low doses.
⚠️ Low-dose efficacy gap risks limiting Novo Nordisk revenue if patients avoid higher doses.
💰 Hedge fund positions surged to $17.24B for Lilly but only $2.00B for Novo Nordisk.
🚀 Novo Nordisk pursues oral treatments like Wegovy pills to diversify beyond injections.
⚠️ CagriSema showed less weight loss than Lilly's Zepbound, reinforcing competitor lead.
📉 Low-dose tirzepatide achieved 5.5% weight loss over one year versus only 2.2% for low-dose semaglutide, highlighting a significant efficacy gap at starter doses.
💊 Patients on lower doses experienced fewer side effects like nausea but faced other adverse events including kidney injury and muscle cramps with tirzepatide.
📈 The obesity drug market is projected to exceed $100 billion annually by 2030, driving competition between Novo Nordisk and Eli Lilly.
🔬 Novo Nordisk's CagriSema demonstrated less weight loss than Lilly's Zepbound in head-to-head testing, reinforcing Lilly's competitive lead.
💰 Hedge fund positions surged for Eli Lilly to $17.24 billion while Novo Nordisk saw a more modest rise to $2.00 billion in the second quarter.
🚀 Novo Nordisk is pursuing oral obesity treatments like Wegovy pills to diversify beyond injections as the global market expands.
⚠️ Substantially lower weight loss at starter doses could limit revenue per patient if users avoid higher maintenance doses due to cost or tolerability.
🏥 Lilly's tirzepatide showed higher rates of constipation and muscle cramps compared to semaglutide, influencing physician and patient preferences.
📊 Novo Nordisk faces pressure from Lilly despite the expanding market, requiring its pipeline and oral treatments to regain momentum.
🌍 Both companies benefit from wider treatment access enabled by low-dose options, though this may come at the expense of treatment intensity.
Haleon (HLN) is capitalizing on the side effects of GLP-1 weight-loss drugs, which are prescribed to millions of users including those taking Novo Nordisk's products. The company revealed a retail strategy on Sept. 16 involving dedicated 'GLP-1 destination shelves' at CVS Pharmacy to sell its Advil, TUMS, and Biotène brands for nausea, cramps, heartburn, and dry mouth.
Early results indicate the strategy is effective, with Haleon reporting an average 24% sales lift per store during the first quarter of 2026. The company holds the majority of GLP-1 shelf space at CVS, noting that products on these dedicated shelves outperform those in regular aisles. CEO Brian McNamara highlighted a good first-half performance with sequential improvement in Q2 and a balanced price/volume mix.
While the approach has succeeded at CVS, Haleon is exploring similar partnerships with Walmart and Target to expand its revenue driver. However, risks remain as CVS promotes its own store brands alongside Haleon's, potentially affecting pricing power, and newer oral GLP-1 pills may have milder side effects that could reduce demand for Haleon's symptom-relief products over time.
Analysts are divided on the stock's outlook; 11 of 17 analysts rate Haleon a Buy with an average target of 420.24 GBX, while Deutsche Bank maintains a Sell rating citing rising input costs and competition from cheaper store brands. The company's shares have declined 8.86% year-to-date as investors remain cautious about growth outside the GLP-1 opportunity.
📈 CVS GLP-1 shelf strategy drove 24% average sales lift in Q1 2026.
🚀 Company plans to expand high-growth shelf placement to Walmart and Target.
⚠️ CVS store brands may erode Haleon's pricing power over time.
💊 Milder side effects from oral pills could reduce long-term demand for relief products.
👍 11/17 analysts rate Haleon a Buy with average target of 420.24 GBX.
📈 Haleon launched a dedicated 'GLP-1 destination shelf' strategy at CVS Pharmacy to capture revenue from patients managing side effects of weight-loss drugs.
💰 The new retail approach delivered an average 24% sales lift per store during the first quarter of 2026 according to company data.
🤝 Haleon holds the majority of GLP-1 shelf space at CVS, with products on dedicated shelves performing better than those in standard aisles.
🚀 The company is actively discussing expanding this high-growth shelf-placement strategy to Walmart and Target retailers.
⚠️ CVS confirmed it is promoting its own store brands alongside Haleon's national brands, which could erode Haleon's pricing power over time.
💊 As newer oral GLP-1 pills replace injectable versions, side effects may become milder, potentially reducing the long-term need for Haleon's symptom-relief products.
📉 Haleon shares are down 8.86% for the year and trade well below their 52-week high of 416.10 GBX as investors weigh growth uncertainties.
👍 Eleven out of 17 analysts rate Haleon a Buy with an average 12-month price target of 420.24 GBX, citing the GLP-1 opportunity.
📉 Deutsche Bank maintains a Sell rating on Haleon with a 320 GBX target due to rising input costs and competition from store brands.
📊 CEO Brian McNamara reported that 73% of Haleon's portfolio gained or maintained market share during the first half of 2026.
Novo Nordisk (NVO) shares rose 3.55% following two key developments: a strategic partnership with AI firm Anthropic and a positive European Medicines Agency recommendation for its hemophilia drug, Frehemgo. The collaboration aims to utilize Anthropic's Claude Science platform to accelerate internal software development and shorten drug discovery timelines, a move supported by Novo CEO Mike Doustdar who views AI as essential for compressing the path from research to market.
The company is also navigating intense competition in its core GLP-1 weight-loss segment, which has contributed to a roughly 20% stock decline over the past year. To address this, Novo recently rebranded, dropping 'Nordisk' from its name and adopting a new logo. Despite these challenges, the regulatory green light for Frehemgo represents a significant milestone, offering patients with hemophilia A greater flexibility through a prefilled pen device with dosing options ranging from weekly to monthly.
Frehemgo demonstrated efficacy in clinical trials under the FRONTIER program, showing reduced annualized bleeding rates compared to existing treatments. The European approval covers both adults and children, including those with inhibitors, marking a major expansion for Novo's portfolio outside of its weight-loss drugs. While the industry has seen AI investments from rivals like Eli Lilly and Merck, no AI-discovered drug has yet received regulatory approval, making this strategic shift particularly notable.
📈 NVO stock rose 3.55% on Anthropic partnership for AI-driven drug discovery.
💊 EMA recommended Frehemgo approval for hemophilia A patients with or without inhibitors.
📉 Shares fell ~20% annually due to intensifying GLP-1 weight-loss drug competition.
🔄 Novo rebranded, dropping 'Nordisk' name and logo to signal fresh direction.
🔬 FRONTIER trial data showed Frehemgo reduced bleeding rates vs existing treatments.
📈 NVO stock climbed 3.55% after announcing a partnership with Anthropic to leverage AI for accelerating drug discovery and internal software development.
🤝 The collaboration utilizes Anthropic's Claude Science platform, aiming to shorten research timelines and improve treatment outcomes as stated by company leadership.
💊 EMA panel recommended approval of Frehemgo, Novo's injectable treatment for hemophilia A, covering adults and children with or without inhibitors.
📉 NVO shares have fallen approximately 20% over the past year due to intensifying competition in the GLP-1 weight-loss drug market.
🔄 The company unveiled a rebranding strategy, dropping 'Nordisk' from its name and adopting a new logo to signal a fresh direction.
💉 Frehemgo will be sold in a single-use prefilled pen offering flexible dosing options ranging from once weekly to once monthly.
🔬 Clinical trial data from the FRONTIER program showed Frehemgo reduced annualized bleeding rates compared to existing clotting-factor treatments.
🏆 Rivals including Eli Lilly, Merck, and Roche have also made significant AI investments in drug discovery and clinical trial automation.
⚠️ While industry peers are investing in AI, no AI-discovered drug has yet received regulatory approval as of the article's publication.
Bullish Signals
Stock rallied 3.55% on Anthropic partnership for faster research.
EMA gave positive recommendation for Frehemgo hemophilia treatment.
New Frehemgo pen offers flexible weekly to monthly dosing.
Risk Factors
Stock down 20% amid rising GLP-1 competition.
Faces pressure from rivals with AI investments.
Bullish Signals
Novo Nordisk stock rallied 3.55% following a strategic partnership with Anthropic designed to compress research timelines and improve internal software development.
The European Medicines Agency issued a positive recommendation for Frehemgo, an injectable treatment for hemophilia A that covers both adults and children.
Clinical trial data from the FRONTIER program demonstrated that Frehemgo reduced annualized bleeding rates compared to existing clotting-factor treatments.
The new Frehemgo formulation offers patients greater flexibility with a single-use prefilled pen and dosing options ranging from once weekly to once monthly.
Risk Factors
Novo Nordisk stock has declined approximately 20% over the past year as competition in the GLP-1 weight-loss drug space intensifies.
The company is facing pressure from rivals like Eli Lilly, Merck, and Roche who have all made significant AI investments to maintain their competitive edge.
Novo Nordisk (NVO) shares rose 2.83% to $42.89 after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on FREHEMGO, a next-generation bispecific antibody for haemophilia A. The regulatory body recommended marketing authorization for denecimig in adults and children with or without factor VIII inhibitors, signaling strong progress toward commercial approval across the European Union.
The drug's development was supported by data from the FRONTIER clinical programme, which demonstrated low bleeding rates and reduced annualised bleeding episodes compared to previous treatments. Phase three studies showed that mean annualised bleeding rates generally remained below one, with a substantial portion of participants recording no treated bleeding episodes during trials involving weekly, biweekly, or monthly dosing schedules.
Novo Nordisk plans to launch FREHEMGO in selected European countries during the fourth quarter of 2026, followed by a broader EU rollout beginning in early 2027. The company has also submitted a Biologics License Application to the US FDA in September 2025, aligning with its long-term strategy to expand its haemophilia treatment portfolio over four decades of research and development.
Additional clinical data from FRONTIER 4 and FRONTIER 5 confirmed the safety profile across different dosing schedules and supported the transition of patients from emicizumab to denecimig. These findings reinforce the drug's potential as a routine preventive treatment option, offering flexibility in administration via pre-filled pens for diverse patient needs.
📈 Novo Nordisk stock rose 2.83% after positive EU CHMP recommendation for FREHEMGO.
💉 FREHEMGO offers weekly to monthly dosing via pre-filled pens for haemophilia A.
🩸 Trials show low bleeding rates and reduced annualised episodes in adults and children.
📅 Initial European launches scheduled for Q4 2026 with broader rollout in early 2027.
🇺🇸 FDA Biologics License Application submitted in September 2025 to expand global portfolio.
📈 Novo Nordisk stock climbed 2.83% to $42.89 following a positive CHMP recommendation for FREHEMGO (denecimig) for haemophilia A treatment in the EU.
💉 FREHEMGO is a next-generation factor VIIIa mimetic bispecific antibody designed for weekly, biweekly, or monthly dosing schedules using pre-filled pens.
🩸 Clinical trials showed low bleeding rates and reduced annualised bleeding episodes compared to previous preventive and on-demand treatments in adults and children.
📅 Novo Nordisk plans initial European launches of FREHEMGO during the fourth quarter of 2026 with a broader EU rollout starting in early 2027.
🇺🇸 The company submitted a Biologics License Application to the US FDA in September 2025, expanding its haemophilia treatment portfolio globally.
👶 FRONTIER 3 trials confirmed consistent efficacy and safety in children below 12 years, matching results seen in adolescents and adults.
🔄 FRONTIER 5 evaluated patients switching from emicizumab to denecimig, identifying no new safety signals following the treatment transition.
🔬 Phase three studies demonstrated that mean annualised bleeding rates generally remained below one across all patient groups studied.
Bullish Signals
Stock gained 2.83% after positive EMA opinion on FREHEMGO.
Bullish Signals
Novo Nordisk stock gained 2.83% to $42.89 after receiving a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on FREHEMGO.
The CHMP recommendation covers adults and children with or without factor VIII inhibitors, expanding the potential market for denecimig in haemophilia A treatment.
Clinical data from the FRONTIER programme showed that FREHEMGO reduced annualised bleeding rates compared with previous preventive and on-demand treatments.
Phase three studies indicated that mean annualised bleeding rates generally remained below one, with a substantial portion of participants recording no treated bleeding episodes.
Novo Nordisk plans to launch FREHEMGO in selected European countries during the fourth quarter of 2026, followed by a broader EU rollout beginning in early 2027.
The company has spent more than four decades developing treatments for haemophilia, positioning FREHEMGO within its wider strategy to expand its haemophilia treatment portfolio.
FRONTIER 5 evaluated patients switching directly from emicizumab to denecimig, identifying no new safety signals following the treatment switch.
Novo Nordisk announced it will present new data from its cardiometabolic pipeline at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, running from September 28 to October 2, 2026. The presentations cover a broad range of scientific insights related to obesity, type 2 diabetes, cardiovascular health, kidney disease, and liver outcomes, reflecting the company's strategic focus on interconnected cardiometabolic diseases.
Key highlights include real-world evidence for the Wegovy® pill regarding appetite regulation and eating behavior, alongside fMRI data exploring brain responses to food cues. Additionally, Novo will share CagriSema data in type 2 diabetes focusing on body composition and organ-level fat remodelling mechanisms, as well as new findings on semaglutide addressing excess liver fat in people with obesity.
The company also plans to present real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes who escalate to semaglutide 2.0 mg versus those switching to tirzepatide. Martin Holst Lange, executive vice president of Research & Development and chief scientific officer, emphasized that these findings have the potential to shape the next generation of cardiometabolic care.
The event will feature oral presentations on CagriSema, zenagamtide, Wegovy® (both injection and tablets), and UBT251. Novo Nordisk is hosting an International Press Briefing on September 30, 2026, which will be accessible via webcast to share the breadth and progression of its portfolio.
📅 Novo Nordisk presents new cardiometabolic data at EASD 2026 in Milan.
🧬 Company showcases real-world evidence for Wegovy® pill appetite regulation.
🧠 fMRI data shared on CagriSema's impact on body composition and brain.
💊 Oral presentations cover CagriSema, zenagamtide, Wegovy®, and UBT251 drugs.
🗣️ Findings may shape future cardiometabolic care strategies for Novo Nordisk.
📅 Novo Nordisk will present new cardiometabolic data at the EASD 2026 meeting in Milan from September 28 to October 2.
🧬 The company will showcase real-world evidence for the Wegovy® pill regarding appetite regulation and eating behavior.
🧠 fMRI data will be shared exploring brain responses to food cues and CagriSema's impact on body composition.
🩺 Novo will present findings on semaglutide addressing excess liver fat in patients with obesity.
⚖️ A comparative study will be presented on major adverse cardiovascular events between escalating to semaglutide 2.0 mg and switching to tirzepatide.
💊 Oral presentations will cover CagriSema, zenagamtide, Wegovy®, and UBT251 across diabetes and obesity indications.
🗣️ Martin Holst Lange highlighted the potential of these findings to shape future cardiometabolic care strategies.
📡 An International Press Briefing is scheduled for September 30, 2026, available via webcast on the Novo website.
Bullish Signals
Novo Nordisk advances cardiometabolic portfolio with new data at EASD 2026.
Semaglutide shows broad benefits for obesity, T2D, and liver health.
Bullish Signals
Novo Nordisk is advancing its cardiometabolic portfolio with new real-world data and clinical insights presented at EASD 2026.
The company is demonstrating broad benefits of semaglutide across multiple indications, including obesity, type 2 diabetes, and liver health.
Novo Nordisk announced positive results from its Phase 3 STEP Young trial, demonstrating that weekly semaglutide combined with lifestyle intervention successfully moved children aged six to twelve below the clinical obesity threshold. The study met its primary endpoint for BMI reduction and confirmed safety consistent with prior adult data, marking a significant scientific milestone for pediatric weight management.
Despite the clinical success, Novo Nordisk's stock has underperformed, falling 17% over the past year to trade at $43.07. Analysts view the company as fairly valued at an 11x trailing PE with a $47 target price, noting that Wall Street remains hesitant regarding immediate commercial adoption due to significant payer hurdles and ethical scrutiny surrounding pediatric use.
The potential for a pediatric Wegovy label would allow Novo Nordisk to enter an age group currently untouched by Eli Lilly's tirzepatide, potentially extending the franchise before patent pressures mount. However, the company faces challenges including a planned 50% price reduction effective January 1, 2027, reduced Medicaid coverage in several states, and the need for FDA approval before on-label use can begin.
While the pediatric readout represents a long-dated option with earnings impact extending beyond the next several quarters, immediate catalysts remain ahead. Key drivers for future stock repricing include the development of CagriSema and the eventual regulatory filing for pediatric labeling, which analysts expect will be critical for re-evaluating Novo Nordisk's growth trajectory.
📊 STEP Young trial proved semaglutide moved children ages 6-12 below obesity threshold.
📉 Wegovy faces 50% price cut in 2027 and payer hurdles delaying uptake.
🔮 CagriSema and pediatric labeling are primary catalysts to reprice NVO stock.
📊 Novo Nordisk's Phase 3 STEP Young trial proved semaglutide moved children ages 6 to 12 below the obesity threshold while placebo failed to do so.
📉 NVO shares have fallen 17% over the past year, trading at $43.07 despite the positive pediatric data release.
💊 A pediatric Wegovy label would reach an age group Eli Lilly's tirzepatide has not yet touched, extending Novo Nordisk's franchise longevity.
📉 Novo Nordisk faces a 50% list price reduction for Wegovy effective January 1, 2027, complicating adoption economics.
⚖️ Payer hurdles and ethical scrutiny regarding prescribing weight loss drugs to young children are delaying immediate market uptake.
🏥 The drug is currently not approved for children under twelve in the US, requiring a new FDA filing and label expansion.
📈 Novo Nordisk trades at an 11x trailing PE with analysts holding mostly hold ratings and a $47.23 target price.
💰 The Wegovy pill has captured around 90% of the US oral obesity medication market with over 5 million prescriptions.
🔮 CagriSema and pediatric labeling are identified as the primary catalysts that could reprice the stock in the future.
Bullish Signals
STEP Young trial met primary endpoint for BMI reduction in kids 6-12.
Pediatric label expansion creates new market vs. Eli Lilly's tirzepatide.
Risk Factors
Shares fell 17% despite positive trial data.
Wegovy price cut complicates pricing power.
Medicaid cuts delay pediatric market entry.
Bullish Signals
Novo Nordisk's Phase 3 STEP Young trial successfully met its primary endpoint for BMI reduction, proving semaglutide efficacy in children ages 6 to 12.
The pediatric label expansion would allow Wegovy to reach an age group currently untouched by Eli Lilly's tirzepatide, extending the franchise before patent expiration.
Risk Factors
NVO shares have fallen 17% over the past year, trading at $43.07 despite positive trial data, indicating market hesitation on adoption.
Novo Nordisk has announced a ~50% Wegovy list price reduction effective January 1, 2027, which complicates commercial adoption and pricing power.
Medicaid coverage for obesity drugs has been reduced in several states, creating access hurdles that may delay pediatric market entry.
Novo Nordisk (NVO) is executing a major strategic rebranding initiative, simplifying its corporate identity to 'Novo' with the motto 'Lasting Health Starts Now.' This transformation aims to enhance accessibility and public confidence while retaining its legal name, Novo Nordisk A/S. The company is simultaneously launching 'The Novo Way,' a cultural blueprint built on four pillars: customer obsession, competitiveness, clarity, and care and integrity.
CEO Mike Doustdar emphasized that the mission to change people's lives remains unchanged despite the shift in branding. The rebranding is designed to accelerate responsiveness in an increasingly competitive landscape where the company must maintain its position against rivals like Eli Lilly. A comprehensive strategic roadmap detailing these changes will be unveiled at the company's Capital Markets Day scheduled for September 21 in London.
Financially, NVO shares have declined approximately 15% year-to-date and fell 2.14% during trading hours, even as the oral formulation of Wegovy achieved over 3 million prescriptions through June. The company currently holds a 38.8% share of the obesity treatment market in Q2, trailing Eli Lilly's dominant 60.9% share. Recent operational challenges include the termination of three clinical trials for an experimental cardiovascular medication, which has contributed to shareholder apprehension.
Despite the stock decline and competitive pressure, the oral Wegovy launch provided Novo with a timing advantage over rival weight management pills like Foundayo, offering momentum in the direct-to-consumer segment. The company's leadership views this cultural and branding shift as essential to regaining competitive positioning and moving with focus and speed in the evolving pharmaceutical sector.
Novo Nordisk shares plummeted as much as 14% after the Danish pharmaceutical giant warned that sales and operating profit growth will decline between 5% and 13% in 2026. The outlook reflects significant headwinds, primarily driven by lower pricing in its largest market, the United States, and the loss of exclusivity for its blockbuster drugs, Wegovy and Ozempic, in key international markets including China, Brazil, and Canada.
CEO Mike Doustdar acknowledged the challenging environment but expressed confidence in the promising early uptake of the newly launched oral version of Wegovy in the U.S. The company aims to recapture market share against rival Eli Lilly by leveraging this new oral treatment and its next-generation injectable, CagriSema, while expanding availability of Wegovy in more countries.
Financially, Novo reported fourth-quarter net sales of 79.1 billion Danish kroner ($12.5 billion), slightly beating analyst estimates, though operating profit was down 14% year-on-year. Ozempic revenue remained relatively flat at constant exchange rates, while Wegovy sales grew 17%. The company faces a strategic battle to maximize its lead in the direct-to-patient channel before rival tirzepatide products fully capture market share.
📉 Novo lowered 2026 guidance citing U.S. pricing pressure and lost exclusivity in key markets.
💊 Q4 net sales hit $12.5B with Wegovy growing 17% while Ozempic revenue stayed flat.
🚀 CEO highlights strong early adoption of the new oral Wegovy pill for future volume growth.
⚔️ Novo faces fierce competition from Eli Lilly, which has surpassed Novo in U.S. market share.
💰 Company bets on CagriSema and 2026 global rollout to revive stock price and position.
📉 Novo Nordisk shares fell as much as 14% after the company lowered guidance, forecasting a 5% to 13% decline in sales and operating profit for 2026.
💊 The outlook is heavily impacted by significant pricing pressure in the U.S. market and the loss of drug exclusivity in China, Brazil, and Canada.
🚀 CEO Mike Doustdar highlighted strong early adoption of the new oral Wegovy pill as a key driver for future volume growth in the United States.
⚔️ The company is fighting to regain footing against fierce competition from rival Eli Lilly, whose tirzepatide has surpassed Novo in U.S. market share.
📊 Fourth-quarter net sales reached 79.1 billion Danish kroner ($12.5 billion), slightly beating estimates, with Wegovy sales growing 17% to 21.9 billion kroner.
🏥 Ozempic revenue remained flat at constant exchange rates in Q4, bringing in 31.8 billion kroner compared to the prior year period.
🌍 Novo plans to roll out Wegovy in additional markets and introduce a higher 7.2 mg dose in several countries during 2026.
💰 The company is banking on its next-generation injectable CagriSema to help revive its stock price and market position.
🤝 Novo and Eli Lilly agreed to cut prices for their best-selling GLP-1 drugs under a deal with the Trump administration, expected to increase volumes but reduce total sales revenue.
📉 Analysts note that while guidance cuts may trigger further downgrades, investors might view the oral Wegovy launch as a clearing event to buy into the company's potential volume inflection.
Bullish Signals
Q4 net sales reached $12.5 billion, beating estimates.
Risk Factors
Forecasts 5-13% sales/profit decline by 2026 due to lower prices.
Eli Lilly tirzepatide surpassed Novo in U.S. market share.
Ozempic revenue flat at constant exchange rates in Q4.
Semaglutide loses exclusivity in Canada, Brazil, China by 2026.
Bullish Signals
Novo Nordisk reported fourth-quarter net sales of 79.1 billion Danish kroner ($12.5 billion), slightly exceeding analyst estimates of 77.8 billion kroner.
Wegovy sales grew 17% in the fourth quarter to reach 21.9 billion kroner, demonstrating strong momentum for the company's flagship weight-loss drug.
The company has successfully launched an oral version of Wegovy in the U.S., creating a new revenue stream and competitive advantage against injectable-only rivals.
CEO Mike Doustdar expressed confidence in the promising early uptake of the oral pill, which could help close the gap with rival Eli Lilly in the direct-to-patient channel.
Novo plans to expand Wegovy availability to more markets and introduce a higher 7.2 mg dose in several countries during 2026 to drive volume growth.
Risk Factors
The company forecasts a sales and operating profit decline of 5% to 13% for 2026, driven by lower prices in the U.S. and loss of exclusivity abroad.
Novo faces intense competition from Eli Lilly's tirzepatide, which has surpassed Novo in U.S. market share due to more pronounced weight loss effects.
Ozempic revenue remained flat at constant exchange rates in Q4, indicating stagnation in the company's original blockbuster drug.
The loss of exclusivity for Semaglutide in Canada, Brazil, and China in 2026 will expose Novo's portfolio to generic competition in these key markets.
Morgan Stanley downgraded Novo Nordisk (NVO) from Equal-weight to Underweight, citing concerns over a looming patent cliff for its blockbuster drug semaglutide. The analyst team maintained a price target of 250 Danish crowns but warned that the current valuation does not adequately reflect a lackluster medium-term growth trajectory. Following the announcement, NVO shares declined approximately 2.4% during early trading in Copenhagen.
The core of Morgan Stanley's bearish thesis centers on semaglutide, which accounts for 75% of Novo Nordisk's revenue and faces patent expirations in Europe and the United States between the early-to-mid 2030s. While the drug is expected to still represent 59% of total sales in 2031, analysts project only a 4% compound annual growth rate for both revenue and EBIT from 2027 to 2030. This forecast trails the broader European pharmaceutical sector, which Morgan Stanley expects to grow at 4% for revenue and 7% for EBIT during the same period.
Despite acknowledging that Novo Nordisk's oral obesity pipeline could reach $10 billion in annual sales by 2031, analysts caution this will not offset pricing pressures and competitive headwinds. A proprietary survey of primary care practitioners indicates anticipated market share erosion over the next 18 months due to competition from Eli Lilly's existing portfolio and its upcoming retatrutide candidate. Consequently, NVO trades at a 35% premium versus global competitors facing similar patent expiration challenges, such as Sanofi and GSK.
📉 Morgan Stanley downgraded NVO to Underweight with a DKK 250 price target.
📊 NVO shares fell 2.4% in Copenhagen following the analyst downgrade announcement.
💊 Semaglutide revenue faces patent expiration risks starting in the early-to-mid 2030s.
📉 Analysts project only 4% CAGR for NVO revenue and EBIT between 2027 and 2030.
⚠️ Oral obesity pipeline may not offset pricing headwinds and generic competition by 2031.
📉 Morgan Stanley downgraded Novo Nordisk (NVO) from Equal-weight to Underweight while maintaining a price target of 250 Danish crowns.
📊 NVO shares fell approximately 2.4% in Copenhagen trading immediately following the analyst downgrade announcement.
💊 Semaglutide, used in Ozempic and Wegovy, represents 75% of Novo Nordisk's revenue but faces significant patent expiration risks in the early-to-mid 2030s.
📉 Analysts project only a 4% compound annual growth rate for NVO's revenue and EBIT between 2027 and 2030, lagging behind European pharmaceutical sector expectations.
⚠️ Morgan Stanley warns that the company's oral obesity pipeline, projected to hit $10 billion in sales by 2031, will not be enough to offset pricing headwinds and generic competition.
🏥 A proprietary survey suggests NVO faces market share erosion over the next 18 months due to Eli Lilly's portfolio and its upcoming retatrutide candidate launching in 2027.
💰 Novo Nordisk trades at a 35% premium versus global competitors like Sanofi and GSK that face comparable patent expiration challenges, despite trading at a discount to European peers.
🗓️ The company is scheduled for a capital markets presentation on September 21, where management is expected to discuss its oral obesity strategy and business development initiatives.
Bullish Signals
Oral obesity pipeline projected to hit $10B annual sales by 2031.
Semaglutide expected at 59% of total sales in 2031 despite patent expiry.
Risk Factors
MS downgraded to Underweight citing lackluster medium-term expansion.
Revenue risks from semaglutide patent expirations in US/Europe.
Market share erosion expected over next 18 months.
Trades at 35% premium vs peers facing patent risks.
Bullish Signals
Novo Nordisk's oral obesity product pipeline is projected to achieve $10 billion in annual sales by 2031.
Semaglutide is expected to still represent 59% of total sales in 2031, even as patent exclusivity begins to expire.
Risk Factors
Morgan Stanley downgraded the stock to Underweight due to concerns that the current valuation fails to account for a lackluster medium-term expansion trajectory.
The company faces significant revenue risks from semaglutide patent expirations in Europe and the United States during the early-to-mid 2030s.
The company faces anticipated market share erosion over the next 18 months driven by Eli Lilly's existing portfolio and its forthcoming retatrutide candidate.
Novo Nordisk trades at a 35% premium versus global competitors confronting comparable patent expiration challenges, including Sanofi and GSK.
Novo Nordisk faces significant market pressure with its stock trading 30% below its January high, despite an aggressive share buyback program that has spent roughly 9 billion kroner. The company's equity has shed 13% year-to-date, currently trading at €38.41, well below the 50-day moving average of €41.44. Management continues to signal confidence through relentless repurchases, accumulating over 32 million B-shares, yet technical analysts view the chart as damaged due to persistent selling pressure.
The primary driver of investor nervousness is a major setback in its cardiology pipeline, specifically the decision to halt late-stage trials for Ziltivekimab in heart failure. An independent committee cited a low probability of success following a failed cardiovascular outcome readout in July, effectively hollowing out a potential growth driver beyond its core GLP-1 franchise. Only one study remains active for post-heart-attack patients, with results not expected until the first half of 2027.
Despite the cardiology headwinds, Novo Nordisk achieved a milestone in pediatrics with the Phase 3 STEP Young trial showing that 40.4% of children under 12 treated with Wegovy no longer met obesity definitions by the study's end. Concurrently, the company launched its oral Wegovy tablet in Germany, though Citi notes slowing new prescription trends for key GLP-1 products. The upcoming September 21 capital markets day will be critical as management addresses how to fill the pipeline gap left by the cardiology setbacks.
Strategic expansion continues with the inaugural 'Novo Group India Day' highlighting the region's importance as healthcare spending accelerates outside Denmark. While the buyback program aims to support the stock price, the market remains cautious about a thinning pipeline beyond GLP-1 and potential revenue slowdowns. The elevated volatility reflects the tension between management's undervaluation thesis and external concerns regarding the company's growth foundation.
📉 Stock drops 30% from January high despite €38.41 trading and massive buybacks.
💊 Halted late-stage Ziltivekimab heart failure trial due to low success probability.
👶 STEP Young trial shows 40.4% of children under 12 no longer meet obesity definitions.
⚠️ Citi maintains sell rating with €265 target citing slowing GLP-1 prescription trends.
🗓️ Must fill Ziltivekimab pipeline hole ahead of September 21 capital markets day.
📉 Novo Nordisk stock drops 30% from its January high, trading at €38.41 despite a massive share buyback program that has spent roughly 9 billion kroner.
💊 The company halted late-stage trials for Ziltivekimab in heart failure due to a low probability of success following a failed cardiovascular outcome readout.
👶 Novo Nordisk achieved a pediatric milestone with the STEP Young trial, showing 40.4% of children under 12 treated with Wegovy no longer met obesity definitions.
💊 The oral version of Wegovy launched in Germany as the first EU market for the tablet formulation, though Citi notes slowing new prescription trends for key GLP-1 products.
🌏 Novo Nordisk hosted the inaugural 'Novo Group India Day' in Bengaluru, marking the region's strategic importance as healthcare spending accelerates.
📅 The company has a 15 billion kroner buyback envelope running until early February 2027, with management signaling confidence despite weak market tape.
⚠️ Citi maintains a sell rating with a price target of 265 Danish kroner, citing slowing prescription trends and a thinning pipeline beyond GLP-1.
📊 The stock trades significantly below its 50-day moving average of €41.44, requiring a reclaim of this level for any technical recovery to gain credibility.
🗓️ Management must articulate how it intends to fill the Ziltivekimab-shaped hole in its pipeline ahead of the September 21 capital markets day.
Bullish Signals
Buyback of 32M B-shares cost ~9 billion kroner.
STEP Young trial: 40.4% of kids under 12 lost obesity.
Oral Wegovy launched in Germany, first EU market.
India Day held; all four entities operate there.
Risk Factors
Stock dropped 30% from January high, trading below 50-day moving average.
Halted two late-stage Ziltivekimab trials after failed cardiovascular outcome readout.
Citi sell rating with 265 DKK target due to slowing GLP-1 trends.
Growth story faces narrower foundation beyond GLP-1 and potential revenue slowdowns.
Bullish Signals
Novo Nordisk completed a significant share buyback, accumulating 32,034,179 B-shares at an average price of 281.63 Danish kroner with a total outlay of roughly 9 billion kroner.
The Phase 3 STEP Young trial demonstrated that 40.4% of treated children under 12 no longer met the definition of obesity by the study's end, opening a largely untapped age group.
Novo Nordisk launched the oral version of Wegovy in Germany, marking the first EU market for the tablet formulation and diversifying revenue away from injectables.
The company hosted the inaugural 'Novo Group India Day' in Bengaluru, underscoring its geographic ambitions as India is the only country outside Denmark where all four Novo entities operate.
Risk Factors
Novo Nordisk's stock dropped 30% from its January high and has shed 13% since the start of the year, trading well below the 50-day moving average.
The company halted two late-stage trials of Ziltivekimab in heart failure following a failed cardiovascular outcome readout, effectively hollowing out a growth driver.
Citi maintains a sell rating with a price target of 265 Danish kroner based on weekly IQVIA prescription tracking showing slowing new-prescription trends for key GLP-1 obesity products.
The market perceives the company's growth story as standing on a narrower foundation than assumed due to a thinning pipeline beyond GLP-1 and potential revenue slowdowns.
Novo Nordisk shares edged lower by 0.87% to close at EUR 40.00 on the Xetra exchange on September 4, 2026, following a weekly gain of 3.48%. The decline occurred as investors digested recent quarterly results and assessed the competitive landscape within the obesity drug market, particularly regarding upcoming oral therapy developments.
Despite the daily dip, the company reported a significant positive earnings surprise for the second quarter. Revenue reached 78.49 billion Danish kroner against a forecast of 71.45 billion, while earnings per share hit 6.18 kroner compared to a consensus of 5.03 kroner. These strong financial figures suggest that Novo Nordisk is successfully navigating market expectations and maintaining robust growth in its key therapeutic areas.
Market attention remains focused on the company's strategic pivot toward oral weight-loss therapies, which could attract patients preferring non-injection treatments and potentially broaden demand within its core segment. However, analysts are closely monitoring stiff competition from peers like Eli Lilly, which continues to shape investor sentiment regarding Novo Nordisk's long-term market share and pricing power in the obesity treatment sector.
Broader macroeconomic conditions and movements in major European and US indices are also influencing trading sentiment for the Danish pharmaceutical giant. As investors recalibrate risk exposure in healthcare sectors, the interplay between strong recent earnings data and the evolving competitive dynamics of oral versus injectable therapies will likely dictate near-term stock performance.
📉 Novo Nordisk shares dipped 0.87% to EUR 40.00 on Sept 4, 2026.
💰 Q2 revenue beat expectations at 78.49 billion DKK vs 71.45 billion forecast.
📈 EPS surged to 6.18 kroner, exceeding the 5.03 kroner consensus estimate.
💊 Investors watch oral weight-loss therapy development to capture non-injection patients.
⚔️ Intense competition from Eli Lilly influences market sentiment and demand projections.
📉 Novo Nordisk shares closed down 0.87% at EUR 40.00 on September 4, 2026, despite a positive weekly gain of 3.48%.
💰 The company beat second-quarter revenue expectations with 78.49 billion DKK versus a forecast of 71.45 billion DKK.
📈 Earnings per share surged to 6.18 kroner, significantly exceeding the consensus estimate of 5.03 kroner.
💊 Investors are closely watching Novo Nordisk's development of an oral weight-loss therapy to capture patients avoiding injections.
⚔️ Intense competition from Eli Lilly remains a key factor influencing market sentiment and demand projections for obesity drugs.
🌍 Broader European and US equity market movements are impacting trading sentiment for the Danish pharmaceutical giant.
Bullish Signals
Q2 revenue beat forecasts at 78.49 billion DKK.
EPS surprise of 6.18 kroner vs 5.03 consensus.
Oral weight-loss therapy expands patient base.
Risk Factors
Stock fell 0.87% amid Eli Lilly obesity drug competition.
Sentiment cautious on maintaining dominance vs weight-loss rivals.
Bullish Signals
Novo Nordisk reported a strong second-quarter revenue beat of 78.49 billion DKK, surpassing analyst forecasts of 71.45 billion DKK.
The company delivered an impressive earnings per share surprise of 6.18 kroner against the consensus expectation of 5.03 kroner.
Novo Nordisk is advancing an oral weight-loss therapy that could broaden its customer base by attracting patients who prefer non-injection treatments.
Risk Factors
The stock experienced a 0.87% decline on September 4, 2026, as investors weighed stiff competition from peers like Eli Lilly in the obesity drug market.
Market sentiment remains cautious regarding the company's ability to maintain its dominant position against intense rivalry in the weight-loss treatment sector.
Novo Nordisk (NVO) shares fell 1.92% to close at $46.60 following the release of positive results from its STEP Young phase 3 clinical trial. The study, which enrolled 165 children aged six to under 12 with severe obesity across multiple countries, demonstrated that once-weekly semaglutide combined with lifestyle changes helped 40.4% of treated participants move below the obesity classification threshold by week 68.
The trial met its primary endpoint by showing a greater reduction in body mass index (BMI) compared to placebo, with no children on the placebo group achieving similar results. Safety findings indicated that the drug's tolerability profile matched earlier studies for adults and adolescents, with no new concerns identified regarding growth or pubertal development.
Novo Nordisk will present these detailed results at ObesityWeek 2026 in November. While the positive clinical data strengthens the company's pediatric obesity program and addresses a growing global need as childhood obesity rates rise, the stock market reaction was negative, likely due to broader market conditions or investor expectations rather than the trial outcome itself.
👶 Semaglutide helped 40.4% of children aged 6-12 exit obesity classification.
📊 Trial met primary endpoint with significant BMI reductions over 68 weeks.
✅ No new safety concerns emerged regarding growth or puberty in study.
🌍 Study enrolled 165 children using weight-based dosing up to 2.4 mg.
📉 NVO shares dropped 1.92% to $46.60 after reporting positive STEP Young trial results for pediatric obesity.
👶 Semaglutide helped 40.4% of treated children aged six to under 12 exit the obesity classification in the phase 3 study.
📊 The trial met its primary endpoint with significant BMI reductions compared to placebo over a 68-week period.
✅ No new safety concerns emerged regarding growth or puberty, matching earlier semaglutide study profiles.
🌍 The study enrolled 165 children across multiple countries using weight-based dosing up to 2.4 mg.
📅 Novo Nordisk plans to present detailed STEP Young results at ObesityWeek 2026 in November.
Bullish Signals
STEP Young trial met primary endpoint with greater BMI reductions vs placebo.
Safety matched earlier studies; no new growth or pubertal concerns found.
Pediatric data strengthens obesity portfolio as childhood obesity hits 228M by 2040.
Risk Factors
Stock fell 1.92% despite positive trial results.
Bullish Signals
The STEP Young trial successfully met its primary endpoint, demonstrating that semaglutide produced greater BMI reductions than placebo in children with severe obesity.
Safety and tolerability findings matched earlier studies for adults and adolescents, with no new concerns identified regarding growth or pubertal development.
The positive pediatric data strengthens Novo Nordisk's obesity treatment portfolio as global estimates suggest childhood obesity could reach 228 million by 2040.
Risk Factors
NVO stock fell 1.92% immediately following the announcement of the positive trial results, indicating a negative market reaction to the news.
Novo Nordisk faces a critical inflection point ahead of its September 21 capital markets day, with shares trading near multi-month lows and under pressure from bearish analyst downgrades. Deutsche Bank recently downgraded the stock to Sell, citing lackluster second-quarter results, cautious guidance, and softer-than-expected Wegovy sales. The company's stock has declined roughly 27 percent from its 52-week high, reflecting growing investor skepticism regarding its growth trajectory amidst intensifying competition.
The bearish outlook is driven by structural headwinds in both the United States and Europe. In the US, Novo Nordisk agreed to significant price cuts for its semaglutide products, including Wegovy and Ozempic, via new channels like TrumpRx, which will compress profitability in its primary growth engine. Simultaneously, rival Eli Lilly has launched its own oral weight-loss drug, Foundayo, while receiving FDA approval for Mounjaro to reduce cardiovascular risk, sharpening the competitive landscape in the GLP-1 arena.
Despite these challenges, China emerges as a potential counterweight to offset growth concerns from Western markets. The Chinese drug regulator has accepted Novo Nordisk's filing for the oral version of Wegovy, opening access to the world's second-largest pharmaceutical market with a massive patient population. This development provides a long-term expansion pathway that could partially mitigate the impact of pricing concessions and rivalry in Europe and the US, though approval timelines remain undisclosed.
📉 Shares down 27% from 52-week high amid cautious investor sentiment.
📉 Deutsche Bank downgraded to Sell with DKK 265 price target.
💊 Eli Lilly's Foundayo approval intensifies GLP-1 competition for Novo Nordisk.
💸 US price cuts via Medicare/Medicaid expected to compress profitability.
🇨🇳 China regulator accepted oral Wegovy filing for market expansion.
📉 Novo Nordisk shares are trading near multi-month lows, down roughly 27 percent from its 52-week high as investor sentiment turns cautious ahead of the September 21 capital markets day.
📉 Deutsche Bank downgraded the stock to Sell with a price target cut to DKK 265, citing lackluster Q2 performance and fundamental doubts about the company's growth trajectory.
💊 Eli Lilly has launched its oral weight-loss drug Foundayo in the UK while receiving FDA approval for Mounjaro's cardiovascular risk reduction label, intensifying competition for Novo Nordisk's GLP-1 portfolio.
💸 Novo Nordisk agreed to cut US prices for Wegovy and Ozempic via Medicare, Medicaid, and TrumpRx channels to $350 per month, a move expected to compress profitability in its primary growth engine.
🇨🇳 China's drug regulator has accepted the filing for oral Wegovy, offering a potential long-term expansion pathway into the world's second-largest pharmaceutical market with a vast patient population.
⚖️ Analyst sentiment remains divided, with Citi maintaining a Sell rating due to slowing prescription trends while JPMorgan holds a Neutral rating, citing the upcoming oral formulation rollout as a potential catalyst.
Bullish Signals
China regulator accepted oral Wegovy filing, opening world's second-largest market.
Launching oral Wegovy in Germany while awaiting EU approval.
Bullish Signals
China's drug regulator has accepted the filing for oral Wegovy, opening access to the world's second-largest pharmaceutical market and providing a long-term expansion pathway to offset growth concerns in Europe and the US.
The company is launching its oral formulation of Wegovy in Germany while awaiting European Commission approval, creating a two-pronged push for its oral product across key markets.
Risk Factors
Deutsche Bank downgraded the stock to Sell and cut its price target to DKK 265, citing lackluster second-quarter results, cautious forward guidance, and softer-than-expected Wegovy sales.
Novo Nordisk agreed to significant price cuts for US semaglutide products via Medicare, Medicaid, and TrumpRx channels, a move that will inevitably compress profitability in its primary growth engine.
Rival Eli Lilly has launched its oral weight-loss drug Foundayo and received FDA approval for Mounjaro's cardiovascular risk reduction label, creating structural headwinds that could weigh on Novo Nordisk's growth prospects.
Citi reaffirmed its Sell rating with a price target of DKK 265, pointing to a slowdown in GLP-1 prescription trends as a key concern for the company's near-term outlook.
Novo Nordisk announced a strategic reshuffle within its research leadership effective October 1, 2026. Andrea Haegebarth, formerly of Bayer, will join as Senior Vice President of Global Research, replacing Jacob Petersen who is moving to lead R&D External Innovation. Executive Vice President Martin Holst Lange described the roles as highly complementary, aiming to strengthen research programs and enhance engagement with global scientific communities to drive meaningful innovation.
The Danish pharmaceutical giant is simultaneously bolstering its pipeline across obesity, diabetes, and related chronic conditions by leveraging its expertise in incretin biology. Key initiatives include advancing CagriSema and a range of next-generation GLP-1 therapies. Additionally, the company is expanding research efforts into cardiovascular disease and rare disorders to diversify its therapeutic portfolio beyond its core metabolic health focus.
The article also covers broader industry developments involving Eli Lilly's Zepbound, which generated US$4.2bn in Q4 2025 revenue and demonstrated lower healthcare costs for users compared to untreated adults. While the text mentions regulatory shifts regarding PFAS chemicals in Sweden and leadership changes at Bupa APAC, these events serve as context rather than primary news for Novo Nordisk.
👤 Novo Nordisk appoints Andrea Haegebarth as SVP of Global Research effective Oct 1, 2026.
🔄 Jacob Petersen moves from Global Research to Head of R&D External Innovation.
🔬 Leadership reshuffle strengthens research programs and connects with global scientific leaders.
💊 Company expands pipeline in obesity, diabetes, and rare disorders using incretin biology.
🚀 Key programs advance CagriSema and next-generation GLP-1 therapies for metabolic health.
👤 Novo Nordisk appoints former Bayer executive Andrea Haegebarth as Senior Vice President of Global Research effective October 1, 2026.
🔄 Jacob Petersen transitions from Global Research to become Head of R&D External Innovation at the company.
🔬 The leadership reshuffle aims to strengthen research programs and connect with global scientific leaders for innovation.
💊 Novo Nordisk continues to expand its pipeline in obesity, diabetes, and rare disorders using incretin biology expertise.
🚀 Key programs include advancing CagriSema and developing next-generation GLP-1 therapies.
❤️ The company is investing in research into cardiovascular disease alongside its core metabolic health portfolio.
Bullish Signals
Strengthening R&D pipeline in obesity/diabetes via incretin biology.
Advancing CagriSema and next-gen GLP-1 therapies.
Bullish Signals
Novo Nordisk is strengthening its R&D pipeline across obesity, diabetes, and related chronic conditions by leveraging deep expertise in incretin biology.
The company is advancing key programs including CagriSema and a range of next-generation GLP-1 therapies to expand its therapeutic offerings.
Novo Nordisk (NVO) shares have declined approximately 49% over the past three years, leading Simply Wall St analysts to conclude the stock may be trading below fair value. The article highlights that current market multiples suggest a more cautious valuation than the company's fundamentals might otherwise support, with sentiment having already reset from earlier optimism.
On key financial metrics, Novo Nordisk trades at a Price-to-Earnings (P/E) ratio of roughly 11.4x, which is significantly lower than the wider pharmaceuticals industry average of 16.2x and the peer group average of 50.1x. Analysts calculate a fair P/E ratio of approximately 29.1x based on broader valuation checks, indicating a substantial discount relative to both historical norms and comparable large drug makers.
Despite growing demand for approved GLP-1 treatments like Wegovy supporting future cash flow expectations, the stock faces an overhang from legal and regulatory risks surrounding obesity and diabetes drugs. The core investment debate centers on whether the current price gap reflects temporary pessimism or a justified warning regarding long-term risks, with community narratives suggesting the company could be up to 51% undervalued if demand sustains.
📉 Novo Nordisk stock down 49% in three years as sentiment resets.
💰 Trades at 11.4x P/E, significantly below industry and peer averages.
📊 Valuation models indicate fair P/E of 29.1x, showing a discount.
💊 Strong demand for Wegovy supports future cash flow expectations.
⚖️ Legal and regulatory risks remain a key overhang for the sector.
📉 Novo Nordisk stock has fallen about 49% over the last three years as sentiment reset from earlier optimism.
💰 The company currently trades at a P/E ratio of 11.4x, well below the industry average of 16.2x and peer group average of 50.1x.
📊 Valuation models suggest a fair P/E ratio of 29.1x, indicating Novo Nordisk is priced at a significant discount to peers.
💊 Growing demand for approved GLP-1 treatments such as Wegovy supports expectations for future cash flows.
⚖️ Legal and regulatory risks around obesity and diabetes drugs remain a key overhang for the entire sector.
📈 Community narratives on Simply Wall St suggest Novo Nordisk could be up to 51% undervalued based on current fundamentals.
Bullish Signals
Novo Nordisk trades at a P/E ratio of 11.4x, which is substantially lower than the wider pharmaceuticals industry average of 16.2x and peer group average of 50.1x.
Valuation checks indicate a fair P/E ratio of 29.1x, suggesting the current market price reflects a significant discount relative to historical norms and comparable large drug makers.
Growing demand for approved GLP-1 treatments like Wegovy supports expectations for future cash flows despite recent share price weakness.
Risk Factors
Recent returns have been weak, with the stock falling about 49% over the past three years, indicating a reset in investor sentiment.
Legal and regulatory risks surrounding obesity and diabetes drugs remain a key overhang for the company and the broader sector.
Novo Nordisk (NVO) has initiated a clinical study to determine the minimum effective dosage for its oral Wegovy weight-loss medication, which utilizes semaglutide. The trial, involving 450 participants with a BMI of at least 27, began on August 12 and is scheduled to run through 2028. It compares two undisclosed reduced dosages against a placebo group to identify optimal treatment levels for managing weight in overweight or obese individuals.
Since the oral Wegovy launched in the United States in January 2026, it has gained significant traction with over 5 million prescriptions filled. The drug generated substantial revenue growth, reaching $500 million in Q2 2026 compared to $350 million in the previous quarter. This momentum is partly driven by reduced-dose formulations priced at approximately 50% of higher-dose options, which have seen robust adoption among patients paying out-of-pocket.
Novo Nordisk's stock price increased by 1.47% following reports of the new trial and strong commercial performance. The company has established a presence in the US, UK, and UAE markets, with leadership expressing optimism that the pill will strengthen its competitive position in the obesity treatment sector. Future findings from this investigation are expected to clarify prescribing protocols and potentially influence strategic product development.
Currently, patients start on a 1.5mg dose of the oral medication, with the ability to escalate up to a maximum of 25mg. The study aims to validate lower dosages that still deliver meaningful clinical results, potentially expanding access for cost-sensitive consumers while maintaining efficacy. This strategic move underscores Novo Nordisk's focus on optimizing its product portfolio and market penetration in the growing obesity therapeutics landscape.
📈 Q2 2026 oral Wegovy revenue hit $500 million, up from $350 million in Q1.
💊 US launch generated over 5 million prescriptions since January 2026.
🔬 New trial starts August 2026 to find minimum effective dosage for 450 participants.
💵 Reduced-dose pricing at 50% of higher doses drives out-of-pocket payer adoption.
📈 Stock rose 1.47% on strong commercial momentum and new trial launch.
📈 Novo Nordisk initiated a clinical study to identify the minimum effective dosage for its oral Wegovy weight-loss medication.
🔬 The trial involves 450 participants with a BMI of at least 27 and will run from August 12 through 2028.
💰 Q2 2026 revenue for the oral Wegovy pill reached $500 million, up from $350 million in Q1 2026.
📊 Since launching in the US in January 2026, the medication has generated over 5 million prescriptions.
💵 Reduced-dose formulations are priced at approximately 50% of higher-dose options, driving adoption among out-of-pocket payers.
📈 NVO stock climbed 1.47% as the company reported strong commercial momentum and launched the new trial.
🌍 Distribution is currently active in the United States, United Kingdom, and United Arab Emirates.
💊 Patients currently start on a 1.5mg dose with potential escalation to a maximum of 25mg.
🎯 The study compares two undisclosed reduced dosages against a placebo to determine optimal effectiveness.
🚀 Novo Nordisk leadership is optimistic the pill will strengthen its competitive position in the obesity sector.
Bullish Signals
Novo Nordisk's oral Wegovy generated $500 million in Q2 2026 revenue, representing significant growth from $350 million in Q1.
The medication has accumulated over 5 million prescriptions since its US launch in January 2026.
Reduced-dose formulations priced at 50% of higher-dose options are driving robust adoption among patients paying out-of-pocket.
NVO stock price increased by 1.47% following the announcement of the new clinical trial and strong sales data.
The company has successfully established its oral semaglutide product in the US, UK, and UAE markets.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)